FDA update: Rotavirus vaccine is not for infants with severe combined immunodeficiency disease
The US Food and Drug Administration has ordered a safety labeling change for RotaTeq oral solution.
The US Food and Drug Administration (FDA) has ordered a safety labeling change for RotaTeq (live pentavalent rotavirus vaccine) oral solution.
Adverse gastrointestinal reactions including gastroenteritis with severe diarrhea and prolonged shedding of vaccine virus have been reported in infants who received the vaccine and later were identified as having severe combined immunodeficiency disease (SCID).
RotaTeq oral vaccine is indicated for the prevention of gastroenteritis in infants and children caused by rotavirus serotypes G1, G2, G3, G4, and P1. It is administered in a 3-dose series to infants between 6 and 32 weeks of age.
Major congenital malformations not linked to first trimester tetracycline use
November 22nd 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Higher pregnancy risks associated with maternal hidradenitis suppurativa
November 8th 2024A study of over 1 million births in Quebec reveals that pregnant women with hidradenitis suppurativa face increased risks of pregnancy complications and long-term health issues for both themselves and their offspring.
